Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline

Stonegate's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary companies, assets, and technologies.

Key Takeaways

  • The market intelligence report identifies a group of small-cap healthcare companies that we believe represent small, undervalued businesses with room to grow in the current biotech industry downturn.
  • The report highlights standout companies including — Alimera Sciences, Inc. (NasdaqGM:ALIM), Assertio Holdings, Inc. (NasdaqCM:ASRT), Aytu BioPharma, Inc. (NasdaqCM:AYTU), Evolus, Inc. (NasdaqGM:EOLS), and Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS) — that not only show strong revenue growth but also low enterprise value to sales ratios.

Dallas, TX - August 8th, 2023 -- Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline examines that represents the top 0.1 percentile of small pharmaceutical growth companies. 

The report highlights standout companies including — Alimera Sciences, Inc. (NasdaqGM:ALIM), Assertio Holdings, Inc. (NasdaqCM:ASRT), Aytu BioPharma, Inc. (NasdaqCM:AYTU), Evolus, Inc. (NasdaqGM:EOLS), and Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS) — that not only show strong revenue growth but also low enterprise value to sales ratios. These characteristics indicate that these companies are potentially undervalued in the market, making them attractive investment opportunities for those seeking growth prospects in the healthcare sector. 

For further information please contact us at info@stonegateinc.com. Please click here to access the report.

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Key Takeaways

  • The market intelligence report identifies a group of small-cap healthcare companies that we believe represent small, undervalued businesses with room to grow in the current biotech industry downturn.
  • The report highlights standout companies including — Alimera Sciences, Inc. (NasdaqGM:ALIM), Assertio Holdings, Inc. (NasdaqCM:ASRT), Aytu BioPharma, Inc. (NasdaqCM:AYTU), Evolus, Inc. (NasdaqGM:EOLS), and Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS) — that not only show strong revenue growth but also low enterprise value to sales ratios.
Access Full Report
Download

Media Gallery

Related Bios

Dave Storms
Director of Research Stonegate Capital Markets
Dave is the Director of Research for Stonegate Capital Markets and provides contract research and valuation services for Stonegate Capital Partners. Dave joined the firm in 2022 and covers multiple sectors. Prior to this, he was an equity research analyst at Goldman Sachs. He was formerly a Senior investment analyst at Beneficial Financial Group, an analyst at Valuation Research Corporation, and an investment analyst with The Board of Pensions (PCUSA) focused on public equities
View Full Bio>>

Contacts

Stonegate Capital Partners
info@stonegateinc.com
(214) 987-4121
General